ABT Abbott Laboratories

Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady dividend cheques from global healthcare stocks can suddenly look more interesting. This piece walks through three healthcare dividend payers from our screener that appear closely exposed to the latest macro news and explains why their stories might matter to...

A secretary at an Illinois pharmaceutical company made a single, unremarkable stock purchase in 1935 and then did almost nothing for the next 75 years. What her college discovered when she died would quietly rewrite everything anyone thought they knew about her.

The latest trading day saw Abbott (ABT) settling at $98.83, representing a -2.1% change from its previous close.

Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test is an FDA-approved blood-based option for average-risk adults who decline traditional colorectal screening methods. Against that product backdrop, Abbott Laboratories has seen its 1 month share price return fall about 10.2%, while the 90 day share price return is up 9.5%. This points to fading short term momentum compared with a still positive multi quarter trend. Recent...

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]

NVST vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]

In recent weeks, Abbott and Berry Street announced an exclusive partnership that combines Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered virtual nutrition coaching, while Abbott’s Volt Pulsed Field Ablation System saw first clinical use in Canada and at UnityPoint Health – Trinity Heart Center in Illinois for treating atrial fibrillation. Alongside these developments, Abbott’s agreement to pay about US$385,000,000 to settle infant formula...

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Focus Wealth Management released its Q2 2026 investor letter. You can download a copy of the letter here. The fund highlighted a period of strong equity market gains as the S&P 500 surged ~17% following March’s selloff, driven by resilient earnings, artificial intelligence (AI) investment, and semiconductor strength. While acknowledging the strength of the AI-driven […]

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Labcorp Holdings stock has outpaced the Dow this year, and analysts remain bullish about its prospects.

Grail stock rose 35% this week as the Food and Drug Administration considers the company’s cancer blood test.

These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.

Markets are wrestling with a Fed that sounds more willing to tolerate economic pain than investors expected, while supply shocks from oil and tariffs keep pressure on costs. That mix tends to push attention toward reliable cash flows and dividends, as many traders reassess how much risk they really want to hold. This article walks through three large-cap, income-focused stocks exposed to this macro backdrop and explains how each may factor into your portfolio decisions now. The stocks below...

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

They have a knack for increasing their dividends even when facing challenges.

Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.

Abbott Laboratories (NYSE:ABT) reached a US$385 million settlement tied to the 2022 infant formula recall and Sturgis plant shutdown. The agreement resolves civil claims from families, states, and other plaintiffs alleging product safety failures and gaps in compliance with federal standards. The settlement follows U.S. Department of Justice and multi state investigations into Abbott's infant formula operations, with no admission of liability. This civil resolution of Abbott's 2022 formula...

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

Abbott Laboratories (NYSE:ABT) has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in potentially contaminated environments at its Michigan and Arizona facilities, including allegations of inadequate testing and failure to disclose positive contamination tests to regulators. The settlement resolves civil claims without an admission […]

Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

Texas is no longer treating every proposed data center as an automatic addition to the grid. On August 3, Governor Greg Abbott ordered an audit of projects moving through ERCOT’s interconnection process, which contained more than 474 gigawatts of requests, over five times the state’s record peak demand. ERCOT began issuing verification requests on September […]

Abbott Laboratories will pay $385 million to resolve claims tied to an investigation of contamination at a baby formula factory in Sturgis, Michigan, the largest in the country, which led to the supply shortages in 2022. Problems at the facility prompted a lawsuit by the Justice Department and recall of powdered infant formula at the facility. The recall covered several infant formula brands, including Similac, and squeezed inventory that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

Some federal prosecutors believed there was enough evidence to bring criminal charges, but Justice Department leadership opted for a civil settlement.

Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.

Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

NVST vs. ABT: Which Stock Is the Better Value Option?

FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.

MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.